Griya Sri Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 14 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 3.50 M
- Revenue Growth -27.59%
- Profit Growth -9.71%
- Ebitda 20.89%
- Net Worth 6.07%
- Total Assets -6.29%
About Griya Sri Pharma
Griya Sri Pharma Private Limited (GSPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 March 2010 and has a history of 14 years and 11 months. Its registered office is in Kanchipuram, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹3.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ramakrishnan Anand and Radha serve as directors at the Company.
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232TN2010PTC074964
- Company No.
074964
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Griya Sri Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramakrishnan Anand  | Managing Director | 17-Mar-2010 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Radha | Additional Director | 30-Apr-2021 | Current |
Financial Performance of Griya Sri Pharma.
Griya Sri Pharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 27.59% decrease. The company also saw a slight decrease in profitability, with a 9.71% decrease in profit. The company's net worth moved up by a moderate rise of 6.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Griya Sri Pharma?
In 2020, Griya Sri Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹3.50 M
Charges Breakdown by Lending Institutions
- Others : 0.35 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Jun 2013 | Others | ₹3.50 M | Satisfied |
How Many Employees Work at Griya Sri Pharma?
Unlock and access historical data on people associated with Griya Sri Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Griya Sri Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Griya Sri Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
